How to Build a Multiplex Biomarker Strategy for ALS Using Olink Explore

ALS biomarker programs increasingly aim to move beyond "one marker, one story." Teams want multiplex protein data that can support three things at once: comparison (how candidates behave relative to each other), prioritization (what to carry forward), and translational interpretation (why a signal might matter in biology and cohort context).

The trap is that "multiplex strategy" can quietly become "measure everything," especially when established and emerging proteins are mixed into one ambitious candidate list. In Olink Explore-based studies, the most important design work often happens before analysis begins: defining what the dataset should help you decide, assigning marker roles, and designing matrix/cohort structure so ranking is interpretable.

We'll use an anonymous mini-case as a through-line: an ALS project that planned to integrate NfL, pNfH, TDP-43, tau, interleukins, CHI3L1 (YKL-40), and ApoA1 to evaluate both individual markers and multi-marker performance—then realized the first step was not choosing the broadest panel, but scoping the study so those proteins could be compared and prioritized without analytical drift.

Figure 1. An ALS biomarker project becomes more actionable when a broad list of established and exploratory proteins is narrowed into a defined multiplex study strategy.

Not every ALS biomarker study is asking the same type of question

A multiplex dataset can support very different goals. Problems begin when a project tries to treat one dataset as simultaneously:

• a broad biology map,
• a marker-ranking engine, and
• a translational framework.

Those outputs require different assumptions and different cohort structures.

Broad neurodegeneration discovery and ALS-focused biomarker strategy are not interchangeable

Broad neurology-oriented profiling can be appropriate when you need to learn what biology is present in your matrices and cohort—especially in early programs or new sample types. But "broad profiling" is not the same thing as an ALS multiplex strategy.

A strategy implies intent: what you will compare, what counts as a meaningful marker in your study, and what "good enough to follow up" looks like.

A marker-ranking project is different from a biology-mapping project

A biology-mapping project can be exploratory ("these pathways differ"). A ranking project can't be that vague. Ranking requires:

• a primary comparison (and optionally a secondary comparison),
• pre-defined evaluation criteria, and
• cohort structure that supports those comparisons.

Without those, a ranked list often becomes an artifact of cohort composition, batch structure, or matrix effects.

The first scoping mistake is treating every ALS-associated protein as equally actionable

In practice, multiplex ALS projects become analytically vague when every plausible ALS-associated protein is treated as equally central. Multiplex design becomes clearer when you assign roles:

• Anchors (reference layer),
• Context markers (mechanism/heterogeneity), and
• Exploratory additions (expansion candidates, not guaranteed "winners").

Start with the study objective before building the multiplex marker strategy

A useful objective statement is simple and testable:

If you can't finish that sentence, the marker strategy will typically expand faster than interpretability.

Are you trying to discover signals, rank candidates, or support a translational framework?

Most ALS multiplex projects sit primarily in one category:

• Broad exploratory profiling: find signals/axes worth follow-up.
• Candidate ranking: compare a defined candidate pool and prioritize a shortlist.
• Translational framework: organize anchors + context into an interpretable model that explains heterogeneity and guides next steps.

One dataset can support multiple aims, but you need a primary objective so the analysis deliverables don't become internally contradictory.

The same marker list can serve very different goals

Using the mini-case list (NfL, pNfH, TDP-43, tau, interleukins, CHI3L1, ApoA1):

• In discovery, the list is "known biology + context," and you expect surprises.
• In ranking, the list is a candidate pool that must be judged against criteria.
• In framework-building, the list becomes marker roles and interpretive layers.

A defined objective makes multiplex results more interpretable

Objective clarity forces three scoping decisions that protect interpretability:

1. Primary comparison (e.g., ALS vs controls; subgroup A vs B; baseline vs longitudinal change).
2. What a ‘priority' marker means (e.g., robust across subgroups; adds incremental value beyond anchors; interpretable in matrix context).
3. What the next step is (focused follow-up, orthogonal measurement, cohort expansion, integrated multi-omics).

Table 1. What kind of ALS biomarker study are you actually designing?

CTA: If your ALS biomarker study currently includes both established and exploratory proteins, share your matrix, cohort structure, and primary biomarker objective with our team so the project can be scoped more clearly before analysis begins.

Established and emerging ALS markers do not all play the same role in a multiplex framework

A frequent failure mode is letting "high interest" become "high priority" automatically. A multiplex strategy stays interpretable when you separate reference, candidate, and context roles.

Some markers anchor the biological relevance of the study

Neurofilament markers are often used as anchors because they are among the more replicated fluid biomarker signals in ALS work. For example, Lu and colleagues' paper on CSF pNfH is part of the evidence base behind pNfH's prominence in ALS biomarker discussions (Lu et al., 2012).

Blood-derived NfL has also been evaluated as an accessible marker with prognostic and stratification relevance in ALS cohorts (for example, Lu et al., Neurology).

In multiplex logic, anchors let you ask a disciplined question: does this candidate add information beyond the anchor layer?

Others expand mechanistic or inflammatory context

Proteins such as interleukins and CHI3L1 (YKL-40) can help interpret inflammatory/glial context and heterogeneity. Their value is often highest when you treat them as context markers that:

• explain why subgroups differ,
• suggest mechanistic clustering, or
• help interpret matrix-specific behavior.

CSF YKL-40 has been assessed as a candidate associated with ALS progression signals (see YKL-40 in sporadic ALS, 2018). In a multiplex strategy, this supports YKL-40 as a context layer marker rather than an always-on anchor.

A multiplex framework should be organized, not just enlarged

A practical role map for the mini-case list:

• Anchors: NfL, pNfH
• High-interest biology-linked candidates: TDP-43, tau
• Context layer (inflammation/systemic): interleukins, CHI3L1 (YKL-40), ApoA1

This doesn't claim any single protein is "the answer." It creates interpretive separation so you can prioritize without flattening everything into one blended signature.

Figure 2. In a multiplex ALS biomarker strategy, established anchors and exploratory context markers play different roles in study design and interpretation.

How to distinguish broad exploratory neuroprotein profiling from an ALS-oriented biomarker strategy

Breadth is useful when it answers a question you actually have. It becomes counterproductive when it substitutes for objective clarity.

Broad neurology-oriented profiling is useful when biology is still unresolved

Broad profiling is a good fit when your program is still learning:

• what the dominant axes of protein variation are in your matrices,
• whether there are distinct biological subgroups,
• whether signals appear consistently enough to justify follow-up.

A neurology-oriented Explore path can be a logical entry point for this phase (see Olink Explore 384 Neurology Analysis and Olink Explore 384 Neurology II Service).

A narrower ALS-oriented strategy makes more sense once the disease question is defined

Once you have a defined comparison and pre-defined prioritization logic, the question often becomes: do we need broad coverage, or do we need a follow-up design that is easier to interpret and scale?

That is where a more focused path may make sense (for example, Olink Target 96 Neurology Panel).

The right analytical breadth depends on what decision the data must support

A scoping rule that prevents "analysis drift":

• If your primary output is pattern discovery, broader coverage can add value.
• If your primary output is candidate prioritization, breadth must be constrained by comparability and role separation.

Matrix and cohort design can reshape the value of ALS biomarker data

Matrix and cohort structure are not "ops details." They often determine whether a multiplex strategy is interpretable.

Matrix choice should follow the translational question, not habit alone

Because you're prioritizing both plasma/serum and CSF, state your matrix intent explicitly:

• Concordance intent: "We want to know which signals show consistent direction across plasma/serum and CSF, recognizing differences in magnitude."
• Division-of-labor intent: "CSF is treated as CNS-proximal biology; plasma/serum adds systemic context and scalability."

Also state whether matrices are paired (same individuals, aligned time points) or unpaired (different subsets). Paired designs support cleaner cross-matrix interpretation; unpaired designs can still be useful but should not be framed as if they support within-subject matrix comparisons.

Cohort structure matters: cases, controls, subgroups, and ALS heterogeneity

ALS heterogeneity is a first-order design constraint, not background noise. Reviews emphasize how heterogeneity affects interpretation and stratification (Balendra & Isaacs, 2020).

If your study will claim "panel interpretability" or "candidate ranking," your cohort must support that claim through:

• case/control logic that matches your primary comparison,
• subgroup structure aligned to your translational question,
• covariate discipline (site, batch, sampling timing).

The value of a multiplex strategy depends on whether the cohort supports the intended comparison

If subgroup comparisons are not supported by cohort structure, do not position the output as subgroup-stable prioritization. Use subgroup analysis as exploratory context instead.

For broader translational planning considerations around inflammatory context and cohort discipline, see Olink Immune Profiling Best Practices for Translational Research.

Figure 3. In ALS biomarker studies, multiplex value depends not only on marker choice, but also on matrix selection, case-control logic, and disease heterogeneity.

Multiplex ALS studies should be designed for prioritization, not just marker accumulation

A useful multiplex strategy narrows ambiguity. A bloated one multiplies narratives.

Adding more proteins is not the same as building a stronger framework

More proteins are helpful only when you can explain:

• what role each marker class plays,
• which subset is eligible for ranking,
• what decision the ranking is meant to support.

A good strategy narrows ambiguity rather than expanding a wish list

Define your prioritization criteria before analysis. Examples:

• Incremental value over anchors: adds information beyond NfL/pNfH.
• Robustness: stable signal across relevant subgroup structure.
• Interpretability: fits an explainable biological layer.
• Follow-up feasibility: lends itself to a focused next-step design.

Ranking logic works best when the project is already biologically structured

Anchors and context markers are not competing for the same job. If you separate their roles, you can prioritize candidates without forcing every protein into a single "top marker" list.

Table 2. What makes an ALS multiplex biomarker strategy more useful—not just broader?

When an ALS study is still broad discovery—and when it is ready for a more focused follow-up path

The transition point is not marker count. It is whether the project can define a stopping rule.

Broad discovery is still useful when the biomarker landscape is unresolved

Broad profiling remains appropriate when:

• your cohort biology is not well characterized in plasma/serum and CSF,
• you need to learn which biological layers dominate variance,
• subgroup structure is not yet stable.

A study becomes follow-up oriented once the marker question is narrowed

You are in follow-up mode when:

• you have a defined candidate pool,
• you can state what would make a candidate "worth carrying forward,"
• you can outline the next-step design.

When focused follow-up becomes the goal, custom approaches can become part of the planning discussion (see Custom Biomarker Set Olink — Flex vs Focus).

The transition point depends on objective, not just marker ambition

A practical checkpoint question:

• "What would make us stop broad profiling and commit to a shortlist?"

How to describe an ALS biomarker project clearly when requesting support

Define matrix and cohort structure first

State matrices, whether samples are paired, cross-sectional vs longitudinal structure, and case/control + subgroup design.

Then state whether the study is broad exploratory, candidate-ranking, or translationally narrowed

Choose one as the primary objective.

Finally explain what decision the protein data is meant to support

Examples: prioritize candidates for follow-up, assess incremental value beyond anchors, map context markers to subgroups.

Micro-checklist

Before submitting your inquiry, clarify:

• matrix type
• case/control and subgroup structure
• whether the study is broad exploratory or already focused
• which markers are established anchors versus exploratory additions
• whether the goal is discovery, ranking, or a translational multiplex framework
• what decision the protein data is expected to support

Common scoping mistakes in ALS multiplex biomarker studies

• Starting with a long marker list before defining the objective.
• Treating all proteins as equivalent in analytical role.
• Ignoring heterogeneity when claiming prioritization.
• Expanding the marker set before the translational question is stable.

Conclusion

A strong multiplex ALS biomarker strategy begins with a defined objective, not a longer marker list. When you assign marker roles (anchors vs context), design the cohort to support real comparisons, and treat matrix choice (plasma/serum and CSF) as part of the interpretation plan, Olink Explore data becomes far more usable for candidate comparison, prioritization, and downstream translational interpretation.

CTA: Planning an Olink Explore-based ALS biomarker study? Send us your matrix, cohort design, candidate-marker priorities, and primary translational question for a preliminary study-scoping discussion via Creative Proteomics Olink.

Author

CAIMEI LI — Senior Scientist at Creative Proteomics
Caimei Li supports Olink proteomics study planning for translational neuroscience, biomarker discovery, and cohort-based protein analysis. Her work focuses on helping research teams define biomarker scope, matrix logic, and analytical strategy before Olink studies begin.
LinkedIn: Caimei Li LinkedIn

Disclaimer

For Research Use Only. Not for use in diagnostic procedures.

FAQs

References

1. Lu et al., 2012 (CSF pNfH)
2. Lu et al., Neurology (Blood-derived NfL)
3. YKL-40 in sporadic ALS, 2018
4. Balendra & Isaacs, 2020